Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):286-99. doi: 10.1016/j.cell.2009.05.045.

2.

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.

Majeti R.

Oncogene. 2011 Mar 3;30(9):1009-19. doi: 10.1038/onc.2010.511. Epub 2010 Nov 15. Review.

PMID:
21076471
3.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R.

PLoS One. 2015 Sep 21;10(9):e0137345. doi: 10.1371/journal.pone.0137345. eCollection 2015.

4.

Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.

Wang Y, Yin C, Feng L, Wang C, Sheng G.

Genet Mol Res. 2015 May 25;14(2):5630-41. doi: 10.4238/2015.May.25.15.

5.

[Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].

Wang YC, Feng L, Yin CY, Ma LN, Wei YW, Wang CM, Sheng GY.

Zhongguo Dang Dai Er Ke Za Zhi. 2013 Jul;15(7):577-82. Chinese.

6.

Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R.

Cancer Res. 2011 Feb 15;71(4):1374-84. doi: 10.1158/0008-5472.CAN-10-2238. Epub 2010 Dec 21.

7.

Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.

Theocharides AP, Jin L, Cheng PY, Prasolava TK, Malko AV, Ho JM, Poeppl AG, van Rooijen N, Minden MD, Danska JS, Dick JE, Wang JC.

J Exp Med. 2012 Sep 24;209(10):1883-99. Epub 2012 Sep 3.

8.

A new therapeutic target for leukemia comes to the surface.

Ritchie DS, Smyth MJ.

Cell. 2009 Jul 23;138(2):226-8. doi: 10.1016/j.cell.2009.07.005.

9.

CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.

Galli S, Zlobec I, Schürch C, Perren A, Ochsenbein AF, Banz Y.

Leuk Res. 2015 Jul;39(7):749-56. doi: 10.1016/j.leukres.2015.04.007. Epub 2015 Apr 20.

PMID:
25943033
10.

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL.

Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375.

11.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R.

Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044.

12.

TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.

Kikushige Y, Akashi K.

Ann N Y Acad Sci. 2012 Aug;1266:118-23. doi: 10.1111/j.1749-6632.2012.06550.x. Review.

PMID:
22901263
13.

[New approaches to target leukemia stem cells].

Takenaka K, Akashi K.

Nihon Rinsho. 2014 Jun;72(6):1018-25. Japanese.

PMID:
25016798
14.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.

15.

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.

Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J, Hase K.

Cancer Med. 2015 Sep;4(9):1322-33. doi: 10.1002/cam4.478. Epub 2015 Jun 16.

16.

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):271-85. doi: 10.1016/j.cell.2009.05.046.

17.

The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.

Iwamoto C, Takenaka K, Urata S, Yamauchi T, Shima T, Kuriyama T, Daitoku S, Saito Y, Miyamoto T, Iwasaki H, Kitabayashi I, Itoh K, Kishimoto J, Kohda D, Matozaki T, Akashi K.

Exp Hematol. 2014 Mar;42(3):163-171.e1. doi: 10.1016/j.exphem.2013.11.005. Epub 2013 Nov 20.

PMID:
24269920
18.

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, Birnbaum D, van Elsas A, Kuijpers TW, Bertucci F, van den Berg TK.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18342-7. doi: 10.1073/pnas.1106550108. Epub 2011 Oct 31.

19.

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL.

Leukemia. 2012 Dec;26(12):2538-45. doi: 10.1038/leu.2012.141. Epub 2012 May 30.

PMID:
22648449
20.

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.

Cell Stem Cell. 2009 Jul 2;5(1):31-42. doi: 10.1016/j.stem.2009.04.018.

Items per page

Supplemental Content

Write to the Help Desk